A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants
研究单位：[1]Bristol-Myers Squibb[2]Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University[3]Women Hospital, School of Medicine, Zhejiang University[4]Third Military Medical University[5]Beijing Friendship Hospital[6]Sichuan Cancer Hospital and Research Institute[7]Tianjin Medical University[8]West China Second University Hospital[9]Xiangya Hospital of Central South University[10]Qilu Hospital of Shandong University[11]Gansu Cancer Hospital[12]Zhejiang Cancer Hospital[13]Shengjing Hospital[14]Anhui Provincial Cancer Hospital
The purpose of this study is to assess the efficacy and safety of the combination of nivolumab and ipilimumab in Chinese participants with malignant pleural mesothelioma.
